PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today issued the following open letter to shareholders from President and CEO, Christopher Anzalone, Ph.D.:
Dear Arrowhead Shareholders,
Market reaction to our AASLD abstract took us by surprise because we have always believed that our public communications surrounding the ARC-520 Phase 2a study have been consistent and, more importantly, properly reflected the data we were seeing in the initial two cohorts. We still believe that, but the market clearly expected something different and/or misunderstood the data. Therefore, I wanted to clarify recent events for our shareholders.
Help employers find you! Check out all the jobs and post your resume.
